

Global Lung Cancer Vaccine Market & Pipeline Insight 2015

<https://marketpublishers.com/r/G6520B8EF20EN.html>

Date: February 2015

Pages: 120

Price: US\$ 1,200.00 (Single User License)

ID: G6520B8EF20EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Lung cancer incidences are rapidly increasing and various therapeutics have been introduced in global market to provide better care to patients. Surgery and radiation therapy are not preferred for lung cancer treatment due to which they have small global market size. Chemotherapeutics and targeted therapeutics for lung cancer treatment are major market contender in global market with wide acceptance levels among oncologists and patients. Chemotherapeutics have life threatening side effects while targeted therapeutics available in markets are quite effective therapeutics but they are unable to reduce the present lung cancer mortality rates. These drawbacks are not expected to be associated with lung cancer vaccines which will help in generating significant revenues and increased penetration across the globe.

Identification of novel targets for lung cancer vaccine development is underway by pharmaceutical companies to provide efficient medical care to patients. Many mechanisms and tumour antigen has been identified for the development of novel lung cancer vaccines. Different lung cancer vaccines will help the patients in deciding better therapeutic options and generate significant revenues for pharmaceutical companies. Pharmacological effects provided by these novel lung cancer vaccine is expected to help the lung cancer patients across the globe.

Melanoma associated antigen 3(MAGE-3) is target of various cancer vaccines for therapeutic treatment of lung cancer. This antigen is absent in normal cell, while it is abundantly found in cancerous cells making it a suitable candidate for developing lung cancer vaccine targeting different stages of cancer progression. These lung cancer vaccines are able to identify different levels of MAGE-3 leading to their correct

identification. As a result, cancer vaccine targeting this antigen is expected to have minimized side effects because it is absent in normal cell. This fact also shows that relapse may not occur due to eradication of all existing cancerous cells from the body.

Lung cancer vaccine is formulated by incorporating MAGE-3 antigen as source of activation for immune cells. This vaccine consists of fusion between human MAGE-3 antigen and protein D from *Haemophilus influenzae*. When it is injected inside the body it causes the immune system to get activated and identify this formulation as external entity. This causes the memory cells to search for any external substances in body having signature sequences like vaccines. As a result, cancerous cells present in the body are identified as external entity and selectively eliminated to prevent the cancer progression.

Lung cancer vaccines are expected to become a major tool in lung cancer treatment in coming years due to superior pharmacological performance. Prophylactic lung cancer vaccines are needed to be developed and thoroughly investigated in clinical trials. Many innovative lung cancer vaccines are under various phases of clinical trials effective medical treatment. Significant clinical data generated has given encouragement to oncologists and pharmaceutical companies to investigate different forms of lung cancer vaccine. These vaccines are under investigation, once high safety and efficacy levels are obtained then it would be easy to apply for the marketing approval across the globe in various countries.

“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:

Introduction to Lung Cancer Vaccine

Global Lung Cancer Vaccine Market Analysis

Global Lung Cancer Vaccine Pipeline by Company & Phase

Global Lung Cancer Vaccine Pipeline: 29 Vaccines

Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines

Marketed Lung Cancer Vaccines: 3 (BV NSCLC 001, Mycidac-C & Vaxira)

Personalized Cancer Vaccines: Progress & Possibilities

Lung Cancer Vaccine Mechanism

Contents

1. INTRODUCTION TO CANCER VACCINES

2. CANCER VACCINES: MECHANISM & INNOVATIONS

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. INTRODUCTION GLOBAL LUNG CANCER VACCINE

4. MECHANISM OF LUNG CANCER VACCINES

5. GLOBAL LUNG CANCER VACCINE MARKET OUTLOOK

- 5.1 Current Market Scenario
- 5.2 Global Lung Cancer Vaccines Pipeline Overview

6. GLOBAL LUNG CANCER MARKET DYNAMICS

- 6.1 Favorable Market Parameters
- 6.2 Market & Commercialization Challenges

7. GLOBAL LUNG CANCER VACCINE MARKET FUTURE PROSPECTS

8. GLOBAL LUNG CANCER VACCINE PIPELINE BY COMPANY & PHASE

- 8.1 Preclinical
- 8.2 Clinical
- 8.3 Phase-I
- 8.4 Phase-I/II
- 8.5 Phase-II
- 8.6 Phase-II/III
- 8.7 Phase-III

9. MARKETED LUNG CANCER VACCINE CLINICAL INSIGHT

9.1 BV NSCLC

9.2 Mycidac-C

9.3 Vaxira®

10. SUSPENDED & DISCONTINUED LUNG CANCER VACCINES PIPELINE BY COMPANY & PHASE

10.1 No Development Reported

10.2 Discontinued

11. COMPETITIVE LANDSCAPE

11.1 Boehringer Ingelheim

11.2 CureVac

11.3 Eli Lilly

11.4 Galaxo

11.5 ImClone Systems

11.6 Merck

11.7 Ono Pharmaceutical

11.8 Oncothyreon Incorporation

List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 3-1: Functions of Lungs

Figure 3-2: Factors Responsible for Increasing Lung Cancer Incidences

Figure 4-1: Type of Lung Cancer

Figure 4-2: Types of Lung Cancer Treatment

Figure 4-3: Mechanism of MAGE-3 Lung Cancer Vaccine

Figure 4-4: Mechanism of p53 Lung Cancer Vaccine

Figure 4-5: Mechanism of NY-ESO-1 Lung Cancer Vaccine

Figure 5-1: Global Lung Cancer Vaccines Pipeline (%), 2015

Figure 5-2: Global Lung Cancer Vaccines Pipeline (Number), 2015

Figure 5-3: No Development Reported in Lung Cancer Vaccines Pipeline (%), 2015

Figure 5-4: No Development Reported in Lung Cancer Vaccines Pipeline (Number), 2015

Figure 5-5: Discontinued Lung Cancer Vaccines Pipeline (%), 2015

Figure 5-6: Discontinued Lung Cancer Vaccines Pipeline (Number), 2015

Figure 6-1: Drivers for Lung Cancer Vaccines

Figure 6-2: Market & Commercialization Challenges

I would like to order

Product name: Global Lung Cancer Vaccine Market & Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/G6520B8EF20EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6520B8EF20EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970